Because of EGFR’s role in the malignant process, elevated expression and accessibility on the tumor cell surface [163, 167, 174, 182, 188–190], EGFR-specific ITs represent highly potent immunotherapeutic agents across a wide range of diseases, including glioblastoma, breast, prostate and pancreatic cancer. This evidence concerns the gene EGFR and pancreatic neoplasm.